Compounded Semaglutide Side Effects and Safety: A Clinical Reference

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

The safety profile of semaglutide is one of the most extensively studied in modern endocrinology. Between the SUSTAIN program in type 2 diabetes, the STEP program in chronic weight management, and the SELECT cardiovascular outcomes trial, the molecule has been studied in tens of thousands of patients over treatment durations exceeding two years. The published adverse event data is detailed, consistent across trials, and broadly reassuring, but it is not zero. Semaglutide is a potent drug with real biological effects, and the side effect profile reflects that.

This page is a clinical reference for what the data actually show. It is written for patients considering compounded semaglutide, for patients already on therapy who want context for symptoms they are experiencing, and for clinicians looking for a plain-language summary they can share with patients. Compounded semaglutide is not FDA-approved, and the safety data discussed here is from trials of the FDA-approved branded products that share semaglutide as the active ingredient. The pharmacological behavior of the active ingredient is the same. The compounded preparation is patient-specific and is dispensed under an individual prescription.

For background on what compounded semaglutide is and the regulatory framework, see the pillar guide.

The Side Effect Categories That Actually Matter

Semaglutide side effects fall into four clinically distinct categories. Lumping them together leads to confusion. Separating them is the first step in understanding which symptoms require a clinical response and which are expected and self-limiting.

The four categories are gastrointestinal effects, metabolic effects, structural and organ-system risks, and theoretical concerns that have been raised in regulatory and academic discussions but do not have established causal evidence.

Gastrointestinal Side Effects

GI side effects are the most common adverse events on semaglutide and account for almost all therapy discontinuations. In STEP-1, 74.2 percent of patients on semaglutide 2.4 mg reported at least one GI adverse event during the 68-week trial, compared to 47.9 percent on placebo. The specific incidence rates were:

Nausea: 44.2 percent on semaglutide versus 16.1 percent on placebo
Diarrhea: 31.5 percent versus 15.9 percent
Vomiting: 24.8 percent versus 6.6 percent
Constipation: 23.4 percent versus 9.5 percent

These events were mostly mild to moderate and concentrated in the early weeks of titration. Most patients who experienced GI symptoms reported that they resolved within a few days of dose escalation. About 7 percent of semaglutide patients in STEP-1 discontinued the drug due to GI adverse events.

The biological mechanism is slow gastric emptying, which is part of how semaglutide produces appetite suppression and is therefore not a side effect that can be eliminated without losing the therapeutic effect. It is a side effect that can be managed.

The management framework is straightforward. Eat smaller meals. Stop eating before you feel full. Avoid high-fat and high-grease foods, which delay gastric emptying further. Limit alcohol, which compounds the GI effects. Stay hydrated, particularly if you have diarrhea or vomiting, because dehydration is the single most common cause of acute kidney complications on GLP-1 therapy. If symptoms are severe enough that you cannot maintain oral hydration, contact your prescribing clinic before continuing therapy.

For specific symptom management, see our supporting article on managing semaglutide nausea.

Metabolic Side Effects

Hypoglycemia is the metabolic adverse event of clinical interest. Semaglutide is not a hypoglycemia-inducing drug as monotherapy in patients without diabetes. GLP-1 receptor agonists have a glucose-dependent insulinotropic effect, meaning they release insulin in response to elevated blood glucose and do not release insulin at normal or low glucose levels. This is fundamentally different from insulin or sulfonylureas.

In patients with type 2 diabetes who are taking semaglutide alongside insulin or a sulfonylurea, hypoglycemia risk increases substantially. This is a drug-interaction risk rather than a direct semaglutide effect, and the standard clinical response is to reduce the dose of the concurrent diabetes medication. Patients in this situation require coordinated care between the semaglutide prescriber and the diabetes care team.

In patients without diabetes, hypoglycemia is uncommon. Reports of low blood sugar symptoms in non-diabetic semaglutide users typically reflect under-eating, alcohol consumption, or a viral illness rather than true biochemical hypoglycemia. If you are experiencing symptoms of low blood sugar, check your glucose with a meter if possible and contact your clinic.

Structural and Organ-System Risks

The structural risks of semaglutide therapy are pancreatitis, gallbladder disease, acute kidney injury, and a category of risks specific to surgery and anesthesia.

Pancreatitis is included in the Wegovy and Ozempic labels as a precaution. The clinical trial data do not establish a clear causal increase in pancreatitis rates compared to placebo, but post-marketing reports have led regulators to require monitoring for symptoms. Acute pancreatitis presents as severe persistent abdominal pain that radiates to the back, often with vomiting. Any patient on semaglutide with these symptoms should stop the drug and seek immediate evaluation. Semaglutide should not be restarted in a patient with a confirmed episode of pancreatitis without specialist evaluation.

Gallbladder disease, including cholelithiasis and cholecystitis, is more common in patients on semaglutide than in patients on placebo. In STEP-1, cholelithiasis was reported in 2.6 percent of semaglutide patients versus 1.2 percent on placebo. The mechanism is thought to relate to rapid weight loss, which is independently associated with gallstone formation, rather than to a direct semaglutide effect on the gallbladder. Patients with a history of gallstones should discuss this risk with their prescribing clinician.

Acute kidney injury has been reported in patients on GLP-1 therapy and is almost always a consequence of dehydration from severe nausea, vomiting, or diarrhea. The kidneys are not a direct semaglutide target. The clinical pattern is a patient who has lost significant fluid volume due to GI symptoms and has not maintained oral hydration. Prevention is hydration. If you cannot keep fluids down, contact your clinic.

Surgical and anesthesia considerations are a newer area of attention. The American Society of Anesthesiologists issued guidance in 2023 recommending that patients on GLP-1 therapy hold the medication before elective surgery due to concerns about residual gastric contents under anesthesia. The current guidance suggests holding semaglutide for at least one week before procedures requiring general anesthesia. Any patient on semaglutide who is scheduled for surgery or a procedure with anesthesia should inform both the surgical team and the prescribing clinician well in advance.

For a deeper discussion of the surgical hold protocol, see our article on semaglutide and surgery: pre-operative protocols.

The Boxed Warning: Thyroid C-Cell Tumors

Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies in which GLP-1 receptor agonists caused medullary thyroid carcinoma in rats and mice. The relevance of this finding to humans is unclear. Humans have very few C-cells in the thyroid compared to rodents, and large-scale human registries have not established a causal increase in medullary thyroid carcinoma in patients on GLP-1 therapy.

The boxed warning is nonetheless a strict contraindication for patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients in these categories should not take semaglutide.

This is one of the screening questions any prescribing clinic should ask before initiating therapy. If you were not asked, that is a meaningful quality signal.

Cardiovascular Safety

The cardiovascular safety of semaglutide was established by the SELECT trial, published in 2023. SELECT enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes, and randomized them to semaglutide 2.4 mg or placebo. The primary endpoint, a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, was reduced by 20 percent in the semaglutide arm over a mean follow-up of 39.8 months.

SELECT was not a safety-only trial, but the safety data were solid and consistent with prior trials. Adverse events leading to discontinuation were more common on semaglutide (16.6 percent versus 8.2 percent on placebo), driven by GI events. Serious adverse events were less common on semaglutide than on placebo (33.4 percent versus 36.4 percent), driven by the cardiovascular benefit.

The SELECT data are the strongest existing evidence that semaglutide's overall risk-benefit profile in patients with established cardiovascular disease is favorable. For patients without cardiovascular disease, the trial does not directly speak to their risk-benefit calculation, but it establishes that the drug does not produce adverse cardiovascular signals at the maintenance dose.

Theoretical and Emerging Concerns

Several concerns have been raised in the academic and regulatory literature that do not yet have established causal evidence but warrant attention.

Mental health and suicidal ideation: The European Medicines Agency reviewed reports of suicidal ideation in GLP-1 users in 2023 and concluded that the available evidence does not support a causal link. The FDA reached a similar conclusion. Both agencies continue to monitor. Patients with a history of depression or suicidal ideation should discuss this with their prescribing clinician and monitor mood actively during therapy.

Muscle mass loss: Rapid weight loss on semaglutide includes loss of lean body mass alongside fat mass, in proportions consistent with calorically-restricted weight loss in general. This is not a unique semaglutide effect. The clinical response is to maintain adequate protein intake (a common target is 1.2 to 1.6 grams of protein per kilogram of body weight) and to perform resistance training. See our supporting article on protecting muscle mass on semaglutide.

Hair shedding: Telogen effluvium, a temporary form of hair shedding, occurs in some patients on semaglutide and is well-described in the rapid weight loss literature. It typically begins three to six months after the start of significant weight loss, resolves spontaneously within six to twelve months, and is not associated with permanent hair loss.

Vision changes: Diabetic retinopathy progression was reported in the SUSTAIN-6 trial in patients with pre-existing diabetic retinopathy. The mechanism is thought to involve rapid glycemic improvement rather than a direct drug effect. Patients with diabetes and retinopathy should have an ophthalmologic evaluation before starting semaglutide.

What to Tell Your Clinician

Before starting semaglutide, your prescribing clinician should know about:

A personal or family history of medullary thyroid carcinoma or MEN 2 (contraindication)
A history of pancreatitis (precaution, may be contraindication depending on history)
A history of gallbladder disease
Current or recent pregnancy or planned pregnancy within two months
All current medications, including oral medications that may have altered absorption due to delayed gastric emptying
Any planned surgery or procedure requiring anesthesia within the next month
A history of eating disorders
A history of severe depression or suicidal ideation

If you are already on semaglutide, contact your clinic for:

Severe persistent abdominal pain that radiates to the back
Persistent vomiting that prevents oral hydration
Signs of dehydration including dizziness, dark urine, or reduced urine output
A planned surgery or procedure
New significant changes in mood or thoughts of self-harm
Vision changes
A new pregnancy or planned pregnancy

This hub is part of the Compounded Semaglutide Side Effects and Safety cluster. Related supporting articles include:

For the foundational overview, return to the pillar guide.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities under individual prescriptions. References: SUSTAIN program (Marso et al., NEJM 2016), STEP-1 (Wilding et al., NEJM 2021), STEP-3 (Wadden et al., JAMA 2021), STEP-4 (Rubino et al., JAMA 2021), SELECT (Lincoff et al., NEJM 2023).

This HealthRX guide is educational and is not a prescription, diagnosis, or substitute for care from a licensed clinician. Compounded semaglutide is not FDA-approved. Treatment decisions should be made with a prescriber who has reviewed your medical history.